Journal
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
Volume 27, Issue 3, Pages 289-291Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0b013e318260ab0a
Keywords
Alzheimer disease; depression; neuropsychiatric symptoms; rivastigmine
Categories
Funding
- Italian Ministry of Health [RC-06-07-08-09-10/A, RF-06-07-08-09]
- Novartis
Ask authors/readers for more resources
Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer's Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n=50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE frequency were evaluated with the Mini Mental State Examination, the CERAD Dysphoria scale and the modified DSM-IV criteria for MDE in AD. MDE frequency reduced significantly from the first diagnostic visit (100%) to the 6-month follow-up (62%). We also found a significant reduction in CERAD Dysphoria scores that decreased from 6.2 +/- 3.9 mean +/- standard deviation to 4.9 +/- 4.5 at the 6-month follow-up. In AD patients with MDE rivastigmine alone can have a positive impact on depressive phenomena. Thus, future controlled study are justified to definitively verify if rivastigmine alone may improve depression in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available